Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Ardelyx, a biopharmaceutical company, announced that its President and CEO, Mike Raab, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.

Ardelyx is focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs. Interested parties can access the live webcast of the presentation on the Ardelyx website. A replay will be available for 30 days post-event.

News Market Reaction

+0.60%

1 alert

+0.60% News Effect

On the day this news was published, ARDX gained 0.60%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

What date and time is the ARDX presentation at the J.P. Morgan Healthcare Conference?

The ARDX presentation is on Wednesday, January 15, 2025, at 4:30pm PT.

Where can I watch the ARDX presentation at the J.P. Morgan Healthcare Conference?

You can watch the live webcast of the ARDX presentation on the Ardelyx website's Events and Presentations page.

How long will the ARDX presentation replay be available?

The replay of the ARDX presentation will be available for 30 days following the event.

Who will present for ARDX at the J.P. Morgan Healthcare Conference?

Mike Raab, President and CEO of Ardelyx, will present at the conference.

What is the focus of Ardelyx as a biopharmaceutical company?

Ardelyx focuses on discovering, developing, and commercializing innovative, first-in-class medicines to meet significant unmet medical needs.